Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech insider sells -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (9)	12/17/2003 12:48:16 PM
From: scaram(o)uche	Respond to of 32

>> a resumption in selling at NBIX << Lyons et al. have done a great job, and a degree of success is in the stock. Focused dilution, issuing modest numbers of shares on strength. They did what a biotech management team SHOULD DO. They have rewarded the patience of early shareholders, addressing a major medical need. Contrast with Vertex, or Kosan. Vertex, just for the embarrassment factor. Kosan is an interesting case..... public company pimps. But the potential upside is large, and greed makes it impossible to sell out with the good profit that I owe to their efforts. ;-)